Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.55 |
| ▸ | CNR1 | P21554 | 10/20 | 0.48 |
| ▸ | CNR2 | P34972 | 9/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | RBP1 | P09455 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | CTSG | P08311 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27957139 | 0.88 | CNR1 (0.47) | TYRCNR1CNR2ALOX5MEN1 | |
| SCHEMBL28270547 | 0.83 | BID (0.50) | CNR1CNR2ALOX5MAPTALOX15 | |
| SCHEMBL28187955 | 0.81 | BID (0.48) | CNR1CNR2ALOX5MAPTALOX15 | |
| SCHEMBL32679952 | 0.79 | CNR1 (0.43) | TYRCNR1CNR2ALOX5MEN1 | |
| SCHEMBL30215704 | 0.79 | CNR1 (0.43) | TYRCNR1CNR2ALOX5MEN1 | |
| SCHEMBL32679953 | 0.79 | CNR1 (0.43) | TYRCNR1CNR2ALOX5MEN1 | |
| SCHEMBL28389443 | 0.78 | NUDT1 (0.38) | CNR1CNR2 | |
| SCHEMBL11022771 | 0.77 | ALOX5 (0.49) | TYRCNR1CNR2ALOX5RBP1 | |
| SCHEMBL7737889 | 0.77 | ACMSD (0.46) | TYRCNR1CNR2ALOX5MEN1 | |
| SCHEMBL28674717 | 0.77 | ELANE (0.44) | TYRCNR1CNR2ALOX5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285687-B2 | Cannabinoids | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2007-10-23 | — | — | US | disclosed |
| US-20050165259-A1 | Such as 2-(3-methylcyclohexyl)-5-(1,1'-dimethylheptyl)-resorcinol for treatment of pain, inflammation and autoimmune disease | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2005-07-28 | — | — | US | disclosed |
| US-20050159449-A1 | Cannabinoids | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165259-A1 | Such as 2-(3-methylcyclohexyl)-5-(1,1'-dimethylheptyl)-resorcinol for treatment of pain, inflammation and autoimmune disease | CNR1, CNR2, HRH4 | TYR 950/4885CNR1 1/4885CNR2 2/4885 |
| US-20050159449-A1 | Cannabinoids | CNR1, CNR2, OPRL1 | TYR 1117/4885CNR1 1/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.